The Staying Power of Small Molecules
October 8, 2026
We asked the 2026 Power List whether newer modalities have eclipsed small molecules – and where the traditional mainstay still wins
4 min read
False
Advertisement
Development & Clinical
Musings from The Power List: Andres Sirulnik
By Andres Sirulnik
October 5, 2026
Regeneron's L. Andres Sirulnik explains why modernizing clinical trials is as important as developing new medicines
4 min read
Development & Clinical
Cell & Gene
Interviews
Business & Trends
Technology & Manufacturing
Power List
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
How Companion Diagnostics Can Support Targeted Drug Launches
By Jane Li
September 29, 2026
Coordinated development and practical testing pathways can help ensure eligible patients are identified from the point of approval
5 min read
Vyriad Begins First-in-Human Trial of In Vivo CAR T Therapy VV169
September 28, 2026
Phase I study will test whether a targeted lentiviral vector can generate BCMA-directed CAR T cells inside patients with multiple myeloma
3 min read
Musings from The Power List: Renee Aguiar-Lucander
September 28, 2026
Renee Aguiar-Lucander argues that faster clinical trials and more pragmatic regulation are essential to bringing medicines to patients sooner
2 min read
Musings from The Power List: Michael May
September 22, 2026
CCRM CEO Michael May on quantum computing, commercialization, and the next era of cell therapy
5 min read
Long-Term Data Boost MCO-010
September 21, 2026
Four-year RESTORE results will shed new light on the durability of Nanoscope’s mutation-agnostic optogenetic therapy
2 min read
Musings from The Power List: Dajun Yang
September 15, 2026
The Ascentage Pharma CEO on why next-generation small molecules are expanding into territory once reserved for biologics
4 min read
